Telix Pharmaceuticals has agreed to lead a merger with ITM Isotope Technologies Munich SE, paying US$1.65 billion upfront on a cash-free, debt-free basis for a German company that supplies the raw material the entire targeted radionuclide therapy industry depends on.
ITM, founded in 2004 and still privately held, is the only producer of globally scaled commercial-grade lutetium-177, and it also produces actinium-225 and terbium-161. Its distribution network reaches more than 65 countries, and through an agreement with Isogen it holds 15-year exclusive access to Bruce Power's nuclear reactors in Canada for the irradiation services needed to make lutetium-177.
Telix has built a commercial franchise on prostate and glioma imaging agents and has three therapeutic candidates in pivotal trials.
ITM delivered annual revenue of US$273 million in 2025, with a compound annual growth rate of 40 per cent since 2021, and its isotope manufacturing arm is profitable and cash generative.
Of the upfront amount, US$1.25 billion goes to sellers as 105.8 million Telix shares priced at the 30-day trailing VWAP at signing of US$11.84, released as Nasdaq-listed American depositary receipts at the end of escrow periods running up to 15 months. Contingent consideration of up to US$700 million follows, comprising up to US$250 million tied to FDA approvals across three indications and up to US$450 million tied to ITM-11 net global sales in 2030 above US$150 million.
Telix management estimates the combined organisation will produce unaudited pro forma 2026 revenue and income exceeding US$1.3 billion, with positive earnings expected from 2027 onward, subject to the realisation of targeted synergies. The global nuclear medicine market is forecast to reach US$41 billion by 2034.
Telix Managing Director and Group CEO Dr Christian Behrenbruch said, "This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures. ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation. We have enjoyed a close working relationship with ITM for many years and there is strong management alignment for the rationale behind this transaction. By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector. Importantly, this combination further expands our late-stage therapeutic pipeline with two completed Phase 3 trials and deepens radioisotope security, while bringing together the mission-critical capabilities needed to deliver radiopharmaceutical treatments to patients around the world."
ITM-11, or lutetium-177 edotreotide, is a somatostatin receptor-targeted treatment for gastroenteropancreatic neuroendocrine tumours that completed a successful Phase 3 trial, COMPETE. A second Phase 3 study, COMPOSE, is fully enrolled with an interim analysis expected in the first half of 2027. If approved, it would give Telix its first foothold in a commercially validated therapeutic market rather than a diagnostic one.
ITM Chief Executive Officer Dr Andrew Cavey emphasised the familiarity between the two management teams. "Joining two radiopharmaceutical pioneers creates a company with unmatched breadth and depth across the value chain, supported by deep expertise and talent. Our management teams have a track record of working together and a nuanced understanding of our respective commercial strengths and customer relationships. Together, we believe Telix and ITM will be uniquely positioned to capitalise on rapidly growing global demand for radiopharmaceuticals to the benefit of both shareholders and patients."
On completion, existing Telix shareholders would hold roughly 76.3 per cent of the company and ITM shareholders 23.7 per cent. The Telix board has approved the transaction, and ITM shareholders holding more than 90 per cent of its shares had signed at the time of announcement, with the remainder expected to sign joinder agreements before closing. Telix shareholders will decide at an extraordinary general meeting expected in November 2026, and the deal is expected to close by the end of financial year 2026.
